ATLANTA, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Medovex Corp. (OTCQB:MDVX) ("Medovex" or the "Company"), the developer of the DenerveX® System, a new and novel device designed for enduring relief of Facet Joint Syndrome related to chronic back pain, a non-addictive, non-opioid drug alternative capable of restoring a patient to a more normal and active lifestyle, today announced that the Company participated at the NSpine Platinum Small Group Educational Event in Arosa, Switzerland, held January 29th through February 3rd, 2018.
Medovex medical advisory board member Vik Kapoor MD, from Manchester, U.K. presented on two separate days at the N-Spine Platinum Small Group Educational Event. Dr. Kapoor presented initial data on his first 20 cases using the DenerveX System, which he considers very positive. The presentation was well received by approximately 50 European neuro, spinal, and orthopedic surgeons. Attending surgeons were granted 30 European CME credits (6 ECMEC® per day) by the European Accreditation Council for Continuing Medical Education (EACCME).
A third day marketing presentation focused on the DenerveX System including discussion related to reimbursement opportunities specific to individual countries, leading to expressed interest from many attendees to start performing DenerveX cases in their respective countries.
In an effort to enhance the value of the meeting, the third day of the event consisted of novel technologies identified by NSpine as improving the field of spine care. The Medovex team was pleased to have been selected.
The value of the Arosa meeting lies in its educational content – to gain a greater understanding of current trends and decision making in spinal surgery – and in the networking with senior decision makers in the world of spinal surgery.
Manfred Sablowski, Medovex Senior Vice President of Global Sales & Marketing stated, “We are pleased to have been selected for participation at The NSpine Platinum Small Group Educational Event. The professional networks built through these events are as valuable as the educational content itself. During this master’s course, Medovex had the privilege of meeting many of the world’s preeminent surgeons who we continue to draw on for advice in managing unusually complex cases.”
Sablowski continued, “Events like these are important milestones for Medovex, as well as a key inflection point gaining us leverage for our Company’s growth strategy focused in Europe, South America, and Australia. Importantly, it provides potential future customers the opportunity to experience firsthand the intuitive DenerveX System.”
Please also follow us on Facebook at https://www.facebook.com/medovex/.
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX System, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com.
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
© 2018 Canjex Publishing Ltd. All rights reserved.